Back to search

Article

Healthcare Utilization and Clinical Outcomes of Lanadelumab: Insights from Spain's First Cohort of Difficult-to-Treat Hereditary Angioedema Patients

2024-10-08

Abstract excerpt

Hereditary angioedema (HAE) is a rare genetic disorder clinically characterized by recurrent episodes of severe swelling, affecting the skin, gastrointestinal tract, and airways. Lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, is approved for long-term prophylaxis (LTP) in HAE patients, demonstrating effectiveness in reducing disease burden. This study evaluated the real-world impact of lanadel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
14c6e919-95f1-58ff-8a17-3e5030d0e380
DOI
10.20944/preprints202410.0490.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Healthcare Utilization and Clinical Outcomes of Lanadelumab: Insights from Spain's First Cohort of Difficult-to-Treat Hereditary Angioedema PatientsDOI 10.20944/preprints202410.0490.v1
Select a neighboring publication to make it the new centre.